Leadership Team
We’re a team of world-class scientists, medicinal chemists, inventors and leaders from top academic and biopharmaceutical institutions, tackling the hardest mental health challenges facing the world today.
Jonathan Sporn, MD
Founder, CEO
25+ years of experience in drug development (Pfizer, JNJ), Assistant Professor of Psychiatry (Columbia University), Founder of Perception Neuroscience (acquired by ATAI Life Sciences), Academic Research (Harvard and NIH)
Andrew Kruegel, PhD
Co-Founder, CSO
Medicinal chemist, 10+ years of experience synthesizing and patenting psychedelic and ibogaine analogs, discovered MOA of the antidepressant Tianeptine, Founder and CSO of Kures Therapeutics (acquired by ATAI Life Sciences)
Gerard Marek, MD PhD
CMO
25+ years of experience in early clinical development and discovery, Assistant Professor of Psychiatry (Yale University School of Medicine), Associate Director (Pfizer), Psychiatric Disorders Discovery Biology CSO (Eli Lilly and Company), Global Medical Lead (Astellas Pharma)
Laszlo Kiss, PhD
CBO and Head of Research
20+ years of experience in drug discovery and development (Merck, Bristol-Myers Squibb), Leadership roles in corporate venture and business development (Pfizer, Biogen)
Yoni Falkson, MBA
COO
15+ years of experience focused on commercial development, payer strategy, marketing and product launches, Co-founder of SpringWorks Therapeutics, Commercial leadership roles at Pfizer and Regeneron
Zoë Hughes PhD
VP of Biology
25+ years CNS drug discovery. Experience in basic and translational pharmacology at GlaxoSmithKline, Wyeth and Pfizer and most recently at Praxis
William Leong, PhD
Exec VP of CMC
30+ years leading and building. CMC/Technical Operations at Celgene and major pharma/biotech, multiple brand approvals and most recently served as VP of CMC at Kymera Therapeutics
.png)
